TNGX
NASDAQTango Therapeutics Inc.
Price$30.93+1.88 (+6.45%)
12:00 PM07:45 PM
News · 26 weeks70-29%
2025-12-142026-06-07
Mix4190d
- Insider13(32%)
- Other11(27%)
- SEC Filings10(24%)
- Analyst5(12%)
- Earnings1(2%)
- Offering1(2%)
Latest news
25 items- INSIDERDirector Ketchum John B was granted 4,000 shares, increasing direct ownership by 19% to 24,937 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- INSIDERDirector Calhoun Lesley Ann was granted 4,000 shares, increasing direct ownership by 32% to 16,500 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- INSIDERDirector Rothenberg Mace was granted 4,000 shares, increasing direct ownership by 11% to 41,500 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- INSIDERDirector Lee Sung was granted 570 shares, increasing direct ownership by 3% to 22,870 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SECSEC Form 424B5 filed by Tango Therapeutics Inc.424B5 - Tango Therapeutics, Inc. (0001819133) (Filer)
- PRTango Therapeutics Announces Proposed $500 Million Public OfferingBOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the launch of an underwritten public offering (the "Offering") of $500 million of its common stock. All shares of common stock to be sold in the Offering will be offered by Tango. Tango also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of shares of its common stock offered in the Offering under the same terms and conditions. The Offering is subject to market conditions, and there can be no assurance as to wh
- ANALYSTTango Therapeutics upgraded by Wolfe ResearchWolfe Research upgraded Tango Therapeutics from Peer Perform to Outperform
- SECTango Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- PRTango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic CancerInitial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of clinical benefit Vopimetostat combinations with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib were generally well-tolerated Data support rapid advancement of vopimetostat plus daraxonrasib combination into Phase 3 development in first-line MTAP deleted pancreatic cancer Conference call today, June 8, 2026, at 8:00am ET BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to
- PRTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that, effective June 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 170,000 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The options have an exercise price of $23.10
- SECSEC Form 8-K filed by Tango Therapeutics Inc.8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- INSIDERPresident, R&D Crystal Adam exercised 27,000 shares at a strike of $5.20 and sold $617,571 worth of shares (27,000 units at $22.87) as part of a pre-agreed trading plan (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tango Therapeutics Inc.SCHEDULE 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
- SECSEC Form SCHEDULE 13G filed by Tango Therapeutics Inc.SCHEDULE 13G - Tango Therapeutics, Inc. (0001819133) (Subject)
- ANALYSTTango Therapeutics downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Tango Therapeutics from Overweight to Neutral and set a new price target of $24.00
- ANALYSTTango Therapeutics downgraded by Jefferies with a new price targetJefferies downgraded Tango Therapeutics from Buy to Hold and set a new price target of $27.00
- SECTango Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- SECSEC Form 10-Q filed by Tango Therapeutics Inc.10-Q - Tango Therapeutics, Inc. (0001819133) (Filer)
- PRTango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business HighlightsFirst clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the first quarter ended March 31, 2026, and provided business highlights. "We continue to work diligently to advance vopimetostat towards pivotal development in pancreatic cancer and remain highly encouraged by the potential of the ongoing study
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tango Therapeutics Inc.SCHEDULE 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tango Therapeutics Inc.SCHEDULE 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
- SECSEC Form 8-K filed by Tango Therapeutics Inc.8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- SECSEC Form SCHEDULE 13G filed by Tango Therapeutics Inc.SCHEDULE 13G - Tango Therapeutics, Inc. (0001819133) (Subject)
- INSIDERPresident, R&D Crystal Adam exercised 27,000 shares at a strike of $5.20 and sold $573,097 worth of shares (27,000 units at $21.23) as part of a pre-agreed trading plan (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- INSIDERChief Financial Officer Gall Matthew was granted 40,000 shares (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
TNGX FAQ
7 questionsWhat does Tango Therapeutics Inc. do?
Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and...Where does TNGX stock trade?
Tango Therapeutics Inc. (TNGX) is listed on NASDAQ.What sector and industry is TNGX in?
Tango Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Tango Therapeutics Inc. go public?
Tango Therapeutics Inc. (TNGX) completed its IPO in 2020.What are analysts saying about TNGX?
Tango Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-06-08. Recent price targets range from $1100.00 to $3000.00.What companies are similar to TNGX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TNGX side-by-side with any of them on Quantisnow.How can I track TNGX on Quantisnow?
Quantisnow aggregates Tango Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TNGX to receive live email and push alerts on every new disclosure.